Affinity Asset Advisors »

Biohaven shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Biohaven (BHVN) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Biohaven

Tip: Access up to 7 years of quarterly data

All positions including Biohaven held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Biohaven by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $784k 30k 26.01

More positions owned by Affinity Asset Advisors

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Apogee Therapeutics (APGE)
Establishment Labs Holdings Ord (ESTA)
Cymabay Therapeutics
Immunovant (IMVT)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Madrigal Pharmaceuticals (MDGL)
Xenon Pharmaceuticals (XENE)
Alkermes SHS Call Option (ALKS)
Kura Oncology (KURA)
Astria Therapeutics (ATXS)
Morphic Hldg (MORF)

View all positions for Affinity Asset Advisors

Top funds holding Biohaven

Stifel Financial
Henderson Group
T. Rowe Price Associates
Point72 Asset Management
Perceptive Advisors
Vanguard Group
Redmile Group
Holocene Advisors
Citadel Advisors
Avidity Partners Management
Bellevue Group
Goldman Sachs Group
Oracle Investment Management
A.R. Schmeidler & Co
Charles Schwab Investment Management

View all funds holding Biohaven